Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology and MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced topline data from the phase 2 MIRAGE study evaluating zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kd") inhibitor, in patients with indolent B-cell Non-Hodgkin
